Treatment of anemia in peritoneal dialysis patients often requires intravenous iron supplementation. Iron diffuses into the peritoneal cavity and is injurious to the peritoneum. We studied how intermittent exposure to iron changes the properties of the senescent peritoneal mesothelial cells (MC).
Methods:
Replicative senescence was induced in MC in control medium (Con) or in control medium with intermittent exposure to iron isomaltoside 15 µg/dL (Con-IIS). After 10 passages properties of MC from both groups were compared to MC not exposed to replicative senescence.
Results:
In senescent MC population doubling time was elongated, intracellular generation of free radicals and staining for β-galactosidase was stronger than in MC not exposed to replicative senescence. All these effects were stronger in MC intermittently exposed to IIS. In these cells intracellular iron content was also higher. Also expression of genes p21 and p53 was stronger in MC intermittently treated with IIS. In senescent cells higher release and expression of IL6 and TGFβ1 was observed and that effect was stronger in MC treated with iron. Senescent MC had reduced fibrinolytic activity, what may predispose to the peritoneal fibrosis. Synthesis of collagen was higher in senescent cells, more in MC treated with iron.
Conclusion:
MC aging results in change of their genotype and phenotype which lead to their profibrotic effect. Exposure to iron enhances these changes.
GotloibLWajsbrotVShostakA. A short review of experimental peritoneal sclerosis: from mice to men. Int J Artif Organs2005; 28: 97–104.
2.
LiakopoulosVRoumeliotisSGornyX, et al. Oxidative stress in patients undergoing peritoneal dialysis: a current review of the literature. Oxid Med Cell Longev2017; 2017: 3494867.
3.
LaheraVGoicoecheaMde VinuesaSG, et al. Oxidative stress in uremia: the role of anemia correction. J Am Soc Nephrol2006; 17(12Suppl 3): S174–S177.
4.
JohnsonDW. Intravenous versus oral iron supplementation in peritoneal dialysis patients. Perit Dial Int2007; 27Suppl 2: S255–S260.
5.
ZagerRA. Intravenous iron therapy in peritoneal dialysis patients: short-term efficacy and long-term issues. Clin J Am Soc Nephrol2006; 1: 353–355.
6.
AgarwalRVasavadaNSachsNG, et al. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int2004; 65: 2279–2289.
7.
ZagerRA. Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy. Kidney Int2005; 68: 1533–1542.
8.
BreborowiczAPołubinskaAKupczykM, et al. Intravenous iron sucrose changes the intraperitoneal homeostasis. Blood Purif2009; 28: 53–58.
9.
MisianMBaumEBreborowiczA, N-acetylcysteine modulates effect of the iron isomaltoside on peritoneal mesothelial cells. J Physiol Pharmacol2020; 71: 365–371.
10.
YamajiYNakazatoYOshimaN, et al. Oxidative stress induced by iron released from transferrin in low pH peritoneal dialysis solution. Nephrol Dial Transplant2004; 19: 2592–25977.
11.
WitowskiJKsiazekKJorresA, New insights into the biology of peritoneal mesothelial cells: the roles of epithelial-to-mesenchymal transition and cellular senescence. Nephron Exp Nephrol2008; 108: e69–e73.
12.
GotloibLGotloibLCKhrizmanV. The use of peritoneal mesothelium as a potential source of adult stem cell. Int J Artif Organs2007: 30: 501–512.
13.
GalarisDMantzarisMAmorgianiotisC. Oxidative stress and aging: the potential role of iron. Hormones2008; 7: 114–122.
14.
RiemerJHoepkenHHCzerwinskaH, et al. Colorimetric ferrozine-based assay for the quantitation of iron in cultured cells. Anal Biochem2004; 331: 370–375.
15.
DimriGPLeeXBasileG, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA1995; 92: 9363–9367.
16.
LivakKJSchmittgenTD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods2001; 25: 402–408.
17.
KsiazekKPiwockaKBrzezińskaA, et al. Early loss of proliferative potential of human peritoneal mesothelial cells in culture: the role of p16INK4a-mediated premature senescence. J Appl Physiol2006; 100: 988–395.
18.
Sosinska-ZawieruchaPMackowiakBBegier-KrasinskaB, et al. L-2-oxothiazolidine-4-carboxylic acids slow down dialysate-induced senescence in human peritoneal mesothelial cells. J Physiol Pharmacol2018; 69: 943–950.
19.
Di PaoloNSacchiGDe MiaM, et al. Morphology of the peritoneal membrane during continuous ambulatory peritoneal dialysis. Nephron1986; 44: 204–211.
20.
JasińskiTBręborowiczA. Adverse effects of iron toward the peritoneal mesothelial cells are reversible. Ther Apher Dial2022; 26: 1247–1255.
21.
ZeidanABhandariS. Anemia in peritoneal dialysis patients: iron repletion, current and future therapies. Dial Int2017; 37: 6–13.
22.
DittrichESchillingerMSunder-PlassmannG, et al. Efficacy of a low-dose intravenous iron sucrose regimen in peritoneal dialysis patients. Perit Dial Int. 2002; 22: 60–66.
23.
KillileaDWWongSLCahayaHS, et al. Iron accumulation during cellular senescence. Ann N Y Acad Sci2004; 1019: 365–367.
24.
KepinskaMSzyllerJMilnerowiczH. The influence of oxidative stress induced by iron on telomere length. Environ Toxicol Pharmacol2015; 40: 931–935.
25.
Lopez-AntonMRudolfABairdDM, et al. Telomere length profiles in primary human peritoneal mesothelial cells are consistent with senescence. Mech Ageing Dev2017; 164: 37–40.
26.
KsiazekKMikula-PietrasikJOlijslagersS, et al. Vulnerability to oxidative stress and different patterns of senescence in human peritoneal mesothelial cell strains. Am J Physiol Regul Integr Comp Physiol2009; 296: R374–R382.
27.
HiguchiCKuriymaJSakuraH. Effect of neutral pH Icodextrin peritoneal dialysis fluid on mesothelial cells. Ther Apher Dial2018; 22: 656–661.
28.
JurkDWilsonCPassosJF, et al. Chronic inflammation induces telomere dysfunction and accelerates ageing in mice. Nat Commun2014; 2: 4172.
29.
NevadoJVallejoSEl-AssarM, et al. Changes in the human peritoneal mesothelial cells during aging. Kidney Int2006; 69: 313–322.
30.
KsiazekKKorybalskaKJörresA, et al. Accelerated senescence of human peritoneal mesothelial cells exposed to high glucose: the role of TGF-beta1. Lab Invest2007; 87: 345–356.
31.
RegulskiMJ. Cellular senescence: what, why, and how. Wounds2017; 29: 168–174.
32.
HolmdahlL. The role of fibrinolysis in adhesion formation. Eur J Surg Suppl1997; 577: 24–31.
33.
BaroniGSchuinskiAde MoraesTP, et al. Inflammation and the peritoneal membrane: causes and impact on structure and function during peritoneal dialysis. Mediators Inflamm2012; 2012: 912595.
34.
BalzerMS. Molecular pathways in peritoneal fibrosis. Cell Signal2020; 75: 109778.
35.
MehtaKJFarnaudSJSharpPA. Iron and liver fibrosis: mechanistic and clinical aspects. World J Gastroenterol2019; 25: 521–538.
36.
XuWDengHHuS, et al. Role of ferroptosis in lung diseases. J Inflamm Res2021; 14: 2079–2090.
37.
AldriweshMAl-DayanNBarrattJ, et al. The iron biology status of peritoneal dialysis patients may be a risk factor for development of infectious peritonitis. Perit Dial Int2019; 39: 362–374.
38.
KsiazekKBreborowiczAJörresA, et al. Oxidative stress contributes to accelerated development of the senescent phenotype in human peritoneal mesothelial cells exposed to high glucose. Free Radic Biol Med2007; 42: 636–341.
